+91-8668442535

Respiratory Tract Infection Treatment Market By Disease (Upper Respiratory Tract Infection, Lower Respiratory Tract Infection), By Drug Class (Antibiotics, Antiviral, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppresant, Nasal Decongestant) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

This report on the global respiratory tract infection treatment market studies various diseases and drug classes. According to the World Health Organization, three million people died from COPD in 2015. The respiratory tract infection treatment market is being driven by a constantly changing climate, rising air pollution, and an increasing desire to maintain personal hygiene. The limiting factors related to this market are the rising incidence of antibiotic resistance and adverse events relating to the consumption of NSAIDs, which will hinder the growth of the respiratory infection treatment market.

Technological advancements in pharmacokinetics and drug screening for adverse events will result in deep market penetration. The increasing consumption of cheap generic medicines will hinder the branded drug market. The drugs in the pipeline are Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead), AZD7594, PT010 (AstraZeneca), etc.

For the purpose of this study, the various diseases studied include upper respiratory tract infection, lower respiratory tract infection, and others. Drug classes studied for the purpose of this research include antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), cough suppressants, nose decongestants, and others.

Upper respiratory tract infection is further segmented as "common cold," "sinusitis," "epiglottitis," and "laryngitis," while lower respiratory tract infection is further segmented as "flu, bronchitis, pneumonia, asthma, COPD, and respiratory syncytial virus." The geographic segmentation of the global respiratory tract infection treatment market is performed for the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. 

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year. This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global respiratory tract infection treatment market.

Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global respiratory tract infection treatment market. The key players profiled in this report are Abbott Laboratories, Abbvie Inc., AstraZeneca, Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, and others.

Based on disease, the global respiratory tract infection treatment market is categorized into

Upper respiratory tract infection

  • Common cold
  • Sinusitis
  • Epiglottitis
  • Laryngitis

Lower respiratory tract infection

  • Flu
  • Bronchitis
  • Pneumonia
  • Chronic obstructive pulmonary disorder (COPD)
  • Asthma
  • Respiratory syncytial virus

A respiratory tract infection is one of the most common reasons for patients to visit the clinic or hospital. In the base year 2016, upper tract respiratory infection held the largest market in the diseased segment due to factors like the constant change in climate and rising air pollution, the rising number of patients suffering from the common cold as many types of viruses cause it, and gross negligence when it comes to personal hygiene like sneezing, coughing (uncovered faces), and touching inanimate objects with contaminated hands.

Lower respiratory tract infection will be the fastest growing market in the diseased segment throughout the forecast period of 2017–2025, chiefly due to factors such as the rising number of airborne particulate matters that are exhumed by industrial chimneys and automobiles that cause lower respiratory tract irritation and infection.

On the basis of transmission, it might be hospital-acquired, ventilator-acquired, or community-acquired. Technological advancement in the exact diagnosis of the causative agent in order to determine the treatment regimen for diseases like asthma, COPD, and the respiratory syncytial virus will be a positive factor for the fast growth of the respiratory tract infection treatment market during the forecast period.

Based on drug class, the respiratory tract infection treatment market is categorized into

  • Antibiotics
  • Antibacterial
  • Cephalosporin (Ceftriaxone, Cefotaxime)
  • Penicillin (Amoxicillin, Ampicillin, and Methicillin)
  • B-lactamase inhibitors (sulbactam, clavulanic acid)
  • Antivirals
  • Ribavarin
  • Palivizumab
  • Ganciclovir
  • Vidarabine

Non-steroidal anti-inflammatory drugs (NSAIDs)

  • Paracetamol
  • Ibuprofen
  • Naproxen
  • Aspirin 

Cough suppressants

  • Dextromethorphan
  • Pholcodine
  • Benzonatate
  • Diphenhydramine

Nasal decongestants

  • Phenylephrine
  • Oxymetazoline
  • Pseudoephedrine
  • Others

Respiratory tract infection treatment is seeing huge application due to factors such as the rising prevalence of respiratory tract infections, the constant change in climate, rising air pollution, and increasing cases of antibiotic resistance. In the base year, 2016, non-steroidal anti-inflammatory drugs (NSAIDS) held the largest market in the drug treatment segment, chiefly due to factors such as low cost, easy availability as OTC products, immediate symptomatic relief, and technological advancement in the drug formulation, e.g., micronized NSAIDs have desirable pharmacodynamic activity and an early excretion rate to overcome NSAID adverse events.

Antibiotics will be the fastest growing market in the drug treatment segment throughout the forecast period of 2017-2025, mainly due to factors such as their diverse application in various respiratory tract infections, improved pharmacokinetics to specifically target the respiratory tract infection (e.g., nebulized Aztreonam formulation is more effective than Aztreonam tablets), and technological advancements in the antibiotics industry are resulting in next-generation broad-spectrum antibiotics (e.g., methicillin formulated with branched polyethyleneimine polymer to counteract antibiotic-resistant cells).

Overall, the global respiratory tract infection treatment market is highly competitive, with multiple players like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim GmbH, Pfizer, Inc., and GlaxoSmithKline plc specializing in their respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the market growth for respiratory tract infection treatment.

For the purpose of this study, the global respiratory tract infection treatment market is categorized into three segments:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

In 2016, North America was identified as the largest market for respiratory tract infection treatment. According to the Centers for Disease Control and Prevention (CDC), American adults have 2 to 3 colds per year with underlying symptoms such as a runny nose, sore throat, coughing, sneezing, headaches, and body aches. The growth is attributed mainly to the large population suffering from respiratory complications and the inclination to maintain personal hygiene, along with a favorable reimbursement scenario.

Europe is expected to be the second-largest market due to cool and damp weather favoring respiratory disease and regulatory approval for respiratory tract infection treatment products. The growth of the Asia Pacific respiratory tract infection treatment market is attributed to factors like the rising prevalence of respiratory illness among a huge population base, a competitive market due to manufacturers involved in respiratory tract infection treatment products, and the impact of monsoon weather in the South Asian countries.

However, factors such as developing health infrastructure, increasing disease awareness, and increasing demand for respiratory tract infection treatment products are going to fuel the growth of the respiratory tract infection treatment market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Question:

The market for Respiratory Tract Infection Treatment Market is expected to reach USD$ 59,957.3 Mn in 2025

The Respiratory Tract Infection Treatment Market is expected to see significant CAGR growth over the coming years, at 6.2 %.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Abbott Laboratories, Abbvie Inc., AstraZeneca, Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58539
Report Format:   PDF
Pages:   120
Rating:    4.6 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support